We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
2
1 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
1
50.0%
Recruiting
No approval data available
- DeepQure's innovative HyperQure™ device demonstrates successful blood pressure reduction in initial trials across South Korea and the United States, with no reported complications. - The company is expanding clinical trials to six leading U.S. universities, including Mayo Clinic and Stanford, aiming to enroll 15 patients in H1 2025 before initiating a pivotal study. - DeepQure is broadening its technology application to treat atrial fibrillation, potentially offering an improved solution to reduce the 30-50% recurrence rates seen with current PVI treatments.
